BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European Neuropsychopharmacology 2012;22:858-66. [DOI: 10.1016/j.euroneuro.2012.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Carl E, Witcraft SM, Kauffman BY, Gillespie EM, Becker ES, Cuijpers P, Van Ameringen M, Smits JAJ, Powers MB. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn Behav Ther 2020;49:1-21. [PMID: 30760112 DOI: 10.1080/16506073.2018.1560358] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 12.5] [Reference Citation Analysis]
2 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015;64:88-98. [PMID: 25851751 DOI: 10.1016/j.jpsychires.2015.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
3 Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian Journal of Psychiatry 2017;26:115-22. [DOI: 10.1016/j.ajp.2017.01.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018;19:1057-70. [PMID: 30056792 DOI: 10.1080/14656566.2018.1491966] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 12.3] [Reference Citation Analysis]
5 Qin B, Huang G, Yang Q, Zhao M, Chen H, Gao W, Yang M. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. BMJ Open 2019;9:e033161. [PMID: 31784448 DOI: 10.1136/bmjopen-2019-033161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kong W, Deng H, Wan J, Zhou Y, Zhou Y, Song B, Wang X. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials. Front Pharmacol 2020;11:580858. [PMID: 33343351 DOI: 10.3389/fphar.2020.580858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
8 Dhir A, Sarvaiya J. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert Rev Neurother 2014;14:1349-63. [PMID: 25418918 DOI: 10.1586/14737175.2014.987131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder: EFFICACY AND TOLERABILITY OF TWO VORTIOXETINE DOSES IN ACUTE GAD. Hum Psychopharmacol Clin Exp 2014;29:64-72. [DOI: 10.1002/hup.2371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
10 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
12 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
13 Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs 2015;20:393-406. [PMID: 26012843 DOI: 10.1517/14728214.2015.1049996] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
14 Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AM, Proctor G, Narayana N, Villa A, Sia YW, Aliko A, McGowan R, Kerr AR, Jensen SB, Vissink A, Dawes C. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D 2017;17:1-28. [PMID: 27853957 DOI: 10.1007/s40268-016-0153-9] [Cited by in Crossref: 107] [Cited by in F6Publishing: 79] [Article Influence: 26.8] [Reference Citation Analysis]
15 Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Psychopharmacology (Berl) 2015;232:7-16. [PMID: 24871704 DOI: 10.1007/s00213-014-3633-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
16 Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68:49-59. [DOI: 10.1111/ijcp.12328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
17 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
18 Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology 2012;22:841-3. [DOI: 10.1016/j.euroneuro.2012.07.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
20 Javelot H. [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives]. Ann Pharm Fr 2016;74:93-118. [PMID: 26472602 DOI: 10.1016/j.pharma.2015.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 He H, Xiang Y, Gao F, Bai L, Gao F, Fan Y, Lyu J, Ma X. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research 2019;118:21-30. [DOI: 10.1016/j.jpsychires.2019.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
22 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
23 Rutherford BR, Bailey VS, Schneier FR, Pott E, Brown PJ, Roose SP. INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS. Depress Anxiety 2015;32:944-57. [PMID: 26437267 DOI: 10.1002/da.22433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
24 Mandrioli R, Mercolini L, Raggi MA. Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety. Expert Opin Drug Metab Toxicol. 2013;9:1495-1505. [PMID: 23834458 DOI: 10.1517/17425255.2013.816675] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
25 Dubovsky SL. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol 2014;10:759-66. [PMID: 24684240 DOI: 10.1517/17425255.2014.904286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekström J, Narayana N, Villa A, Sia YW, Joshi RK, Mcgowan R, Beier Jensen S, Kerr AR, Lynge Pedersen AM, Vissink A. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2015;120:185-206. [DOI: 10.1016/j.oooo.2014.10.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
27 Liebowitz MR, Careri J, Blatt K, Draine A, Morita J, Moran M, Hanover R. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depress Anxiety 2017;34:1164-72. [DOI: 10.1002/da.22702] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 2016;206:140-50. [DOI: 10.1016/j.jad.2016.07.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
29 Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother 2015;16:1669-81. [PMID: 26159446 DOI: 10.1517/14656566.2015.1059424] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
30 Findling RL, Robb AS, DelBello M, Huss M, McNamara N, Sarkis E, Scheffer R, Poulsen LH, Chen G, Lemming OM, Areberg J, Auby P. Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. J Child Adolesc Psychopharmacol 2017;27:526-34. [PMID: 28333546 DOI: 10.1089/cap.2016.0155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
31 Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. Neuropsychiatr Dis Treat 2016;12:951-9. [PMID: 27143896 DOI: 10.2147/NDT.S104050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
32 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
33 Baldwin DS, Hanumanthaiah VB. Vortioxetine in the treatment of major depressive disorder. Future Neurology 2015;10:79-89. [DOI: 10.2217/fnl.14.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
34 Naik H, Chan S, Vakilynejad M, Chen G, Loft H, Mahableshwarkar AR, Areberg J. A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic Clin Pharmacol Toxicol 2016;118:344-55. [DOI: 10.1111/bcpt.12513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Chen TR, Huang HC, Hsu JH, Ouyang WC, Lin KC. Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. J Psychiatr Res 2019;118:73-83. [PMID: 31494377 DOI: 10.1016/j.jpsychires.2019.08.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 7.5] [Reference Citation Analysis]
36 Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Pedersen AM, Vissink A, Aliko A, Sia YW, Joshi RK, McGowan R, Jensen SB, Kerr AR, Ekström J, Proctor G. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis 2016;22:365-82. [PMID: 26602059 DOI: 10.1111/odi.12402] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
37 Ballanger B, Bath KG, Mandairon N. Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging. Neurobiol Aging 2019;82:18-29. [PMID: 31377537 DOI: 10.1016/j.neurobiolaging.2019.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]